LIXTE Biotechnology advances colon cancer treatment with Roche and Netherlands Cancer Institute
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a trailblazer in clinical stage pharmaceutical development, has embarked on a groundbreaking clinical trial in partnership with ... Read More
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of ... Read More